Open-house rebate agreement for Pamidronic acid
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pamidronsäure (ATC-Code nach WHO: M05BA03)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...
Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jan 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Pamidronic acid (ATC M05BA03).
- Open-house participation model allowing eligible pharmaceutical companies to join during the participation period.
Show full summary
This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Pamidronic acid (ATC M05BA03) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. Documents are available via DTVP, but no procurement document text was provided for analysis, so several submission details remain document-dependent and incomplete.
Risks
The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...
Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicines.
- The company must accept the participation conditions and the rebate agreement terms.
Eligibility
- Submission of the completed declaration on the absence of exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for Pamidronic acid
Single lot for concluding non-exclusive pharmaceutical rebate agreements for medicines containing Pamidronic acid (ATC M05BA03). The lot is a supply arrangement under an open-house model; no exclusivity, no guaranteed minimum purchase volume, and the contract may be concluded with all interested eligible pharmaceutical companies during the participation period. Place of performance is Dresden, Germany, with broader reference to Saxony and Thuringia in the XML notice.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pamidronsäure (ATC-Code nach WHO: M05BA03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 19 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 687423-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...
Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications